Clinical

Dataset Information

0

Utility of FDG-PET Scan on the Selection of Patients for Resection of Hepatic Colorectal Metastases


ABSTRACT: Objective(s) of the proposed study: * The evaluation of the efficiency of 18F deoxyglucose-Positron Emission Tomography (FDG-PET) in staging patients eligible for hepatic resection of colorectal liver metastases in a randomized clinical multicentre setting. Research questions of the proposed study: * What are the effects and costs for patients with liver metastases of colorectal cancer indicated for potentially curative hepatic resection, using the conventional diagnostic strategy with computed tomography (CT) scan in comparison to the experimental diagnostic strategy incorporating FDG-PET scan (CT + FDG-PET scan), based on a health care perspective and a time horizon of 9 months. More specifically: * Does the experimental diagnostic strategy which includes FDG-PET scan in the diagnostic work-up of patients eligible for potentially curative hepatic resection of colorectal liver metastases lead to a better disease-free survival at 9 months after hepatic resection in comparison to the conventional diagnostic strategy using CT scan without FDG-PET scan. * What are the costs of diagnostic and therapeutic care for the two diagnostic strategies for patients eligible for potentially curative hepatic resection of colorectal liver metastases. * What is the effect of including the FDG-PET scan in the diagnostic work-up of patients eligible for potentially curative hepatic resection of colorectal liver metastases after hepatic resection, expressed as disease-free survival at 9 months adjusted for quality of health (Q-TWIST), in comparison to the use of CT scan only.

DISEASE(S): Neoplasm Metastasis,Neoplasms, Second Primary,Colorectal Cancer,Colorectal Neoplasms,Colorectal Liver Metastases

PROVIDER: 2013478 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2018-01-01 | GSE69581 | GEO
2019-01-23 | GSE101491 | GEO
2011-11-01 | E-GEOD-21217 | biostudies-arrayexpress
| 18849 | ecrin-mdr-crc
2012-12-01 | E-MEXP-3730 | biostudies-arrayexpress
2022-04-05 | GSE164961 | GEO
| 2747599 | ecrin-mdr-crc
2018-06-06 | GSE99790 | GEO
2021-09-09 | PXD020109 | Pride
2023-12-21 | GSE192464 | GEO